GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Resverlogix Corp (TSX:RVX) » Definitions » Total Liabilities

Resverlogix (TSX:RVX) Total Liabilities : C$109.02 Mil (As of Mar. 2024)


View and export this data going back to 2005. Start your Free Trial

What is Resverlogix Total Liabilities?

Resverlogix's Total Liabilities for the quarter that ended in Mar. 2024 was C$109.02 Mil.

Resverlogix's quarterly Total Liabilities increased from Sep. 2023 (C$107.38 Mil) to Dec. 2023 (C$108.66 Mil) and increased from Dec. 2023 (C$108.66 Mil) to Mar. 2024 (C$109.02 Mil).

Resverlogix's annual Total Liabilities increased from Dec. 2021 (C$89.41 Mil) to Dec. 2022 (C$91.56 Mil) and increased from Dec. 2022 (C$91.56 Mil) to Dec. 2023 (C$108.66 Mil).


Resverlogix Total Liabilities Historical Data

The historical data trend for Resverlogix's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Resverlogix Total Liabilities Chart

Resverlogix Annual Data
Trend Apr14 Apr15 Apr16 Apr17 Apr18 Apr19 Apr20 Dec21 Dec22 Dec23
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 299.68 106.05 89.41 91.56 108.66

Resverlogix Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 99.80 107.38 108.66 109.02

Resverlogix Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Resverlogix's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=36.03+(0+72.63
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=108.66

Total Liabilities=Total Assets (A: Dec. 2023 )-Total Equity (A: Dec. 2023 )
=8.746--99.914
=108.66

Resverlogix's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=39.486+(0+69.53
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=109.02

Total Liabilities=Total Assets (Q: Mar. 2024 )-Total Equity (Q: Mar. 2024 )
=10.079--98.937
=109.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Resverlogix Total Liabilities Related Terms

Thank you for viewing the detailed overview of Resverlogix's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Resverlogix (TSX:RVX) Business Description

Traded in Other Exchanges
Address
4820 Richard Road South West, Suite 300, Calgary, AB, CAN, T3E 6L1
Resverlogix Corp clinical-stage biotechnology company. The company is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with chronic disease including cardiovascular disease (CVD) and associated comorbidities, and COVID-19.
Executives
Aaron Bradley Cann Senior Officer

Resverlogix (TSX:RVX) Headlines

No Headlines